HRB
70
-3
ECL
69
-3
SHW
71
-2
XOM
48
3
AVB
65
-2
SWN
70
3
CNX
76
5
MA
65
-4
TGT
50
2
MPC
44
3
AVY
54
-14
AIG
51
-2
CHRW
48
8
IR
69
-2
ADSK
65
-2
RIG
35
-3
EXC
50
-4
CRM
50
-5
MSI
69
-3
WEC
46
-4
HRB
70
-3
ECL
69
-3
SHW
71
-2
XOM
48
3
AVB
65
-2
SWN
70
3
CNX
76
5
MA
65
-4
TGT
50
2
MPC
44
3
AVY
54
-14
AIG
51
-2
CHRW
48
8
IR
69
-2
ADSK
65
-2
RIG
35
-3
EXC
50
-4
CRM
50
-5
MSI
69
-3
WEC
46
-4
Financhill
Back

Zevra Therapeutics Quote, Financials, Valuation and Earnings

Hedge fund manager warns about the market ahead

Free book prepares you for the coming uncertainty in the stock market
Buy
52

ZVRA
Zevra Therapeutics

Last Price:
8.07
Seasonality Move:
-17.07%

7 Day Trial

ALL ACCESS PASS

$ 7

32,481% Growth? Meet Mode Mobile's "EarnPhone"

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Zevra Therapeutics Price Quote

$8.07
+0.24 (+3.07%)
(Updated: September 19, 2024 at 3:10 PM ET)

Zevra Therapeutics Key Stats

Buy
52
Zevra Therapeutics (ZVRA) is a Buy
Day range:
$7.50 - $8.11
52-week range:
$3.89 - $8.44
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.05
P/B ratio:
12.69%
Volume:
1M
Avg. volume:
762.9K
1-year change:
53.83%
Market cap:
$412M
Revenue:
$27.5M
EPS:
$-1.68

How Much Does Zevra Therapeutics Make?

Is Zevra Therapeutics Growing As A Company?

  • What Is Zevra Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.47%
  • What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Zevra Therapeutics Stock Price Performance

What Is Zevra Therapeutics 52-Week High & Low?

Zevra Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Zevra Therapeutics?

  • How Much Debt Does Zevra Therapeutics Have?
    Total long term debt quarterly is $58.3M
  • How Much Cash Does Zevra Therapeutics Have?
    Cash and short term investments quarterly total is $49.3M
  • What Is Zevra Therapeutics’s Book Value Per Share?
    Book value per share is 0.77

Is Zevra Therapeutics Cash Flow Positive?

  • What Is ZVRA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$56.1M
  • What Is Zevra Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $47.8M
  • What Is Zevra Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$19.2M

Zevra Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ZVRA return on invested capital is -68.51%
  • What Is Zevra Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -46.14%
  • What Is ZVRA Return On Equity?
    ROE is a measure of profitability and is -117.77%

Zevra Therapeutics Earnings Date & Stock Price

Zevra Therapeutics Competitors

  • Who Are Zevra Therapeutics's Competitors?
    Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
    • Arcutis Biotherapeutics Inc (ARQT)
    • BioCardia Inc (BCDA)
    • Crinetics Pharmaceuticals Inc (CRNX)
    • Instil Bio Inc (TIL)
    • Verrica Pharmaceuticals Inc (VRCA)

Zevra Therapeutics Dividend Yield

Zevra Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -9.92%
Revenue: -47.47% 2.09%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 17.60
Upside from Last Price: 124.78%

Major Shareholders

  • How many ZVRA shares are owned by institutional investors?
    24.6M ZVRA shares are owned by institutional investors
  • How many ZVRA shares are owned by insiders?
    286.1K ZVRA shares are owned by insiders